WO2006060819A3 - Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells - Google Patents

Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells Download PDF

Info

Publication number
WO2006060819A3
WO2006060819A3 PCT/US2005/044170 US2005044170W WO2006060819A3 WO 2006060819 A3 WO2006060819 A3 WO 2006060819A3 US 2005044170 W US2005044170 W US 2005044170W WO 2006060819 A3 WO2006060819 A3 WO 2006060819A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunotherapy
dhmeq
chemotherapy
sensitizing agent
cancer cells
Prior art date
Application number
PCT/US2005/044170
Other languages
French (fr)
Other versions
WO2006060819A2 (en
Inventor
Benjamin Bonavida
Original Assignee
Univ California
Benjamin Bonavida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Benjamin Bonavida filed Critical Univ California
Publication of WO2006060819A2 publication Critical patent/WO2006060819A2/en
Publication of WO2006060819A3 publication Critical patent/WO2006060819A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention for the first time identifies DHMEQ as a sensitizing agent for therapy (e.g., chemotherapy, hormonal therapy, radiotherapy and immunotherapy) of resistant and sensitive cells. The present invention therefore provides methods of treating drug and immunotherapy-sensitive cancers and treating drug and immunotherapy -resistant cancers with DHMEQ or structurally similar compounds either alone or in combination with chemotherapy, hormonal therapy, radiotherapy and immunotherapy agents.
PCT/US2005/044170 2004-12-03 2005-12-05 Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells WO2006060819A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63290004P 2004-12-03 2004-12-03
US60/632,900 2004-12-03

Publications (2)

Publication Number Publication Date
WO2006060819A2 WO2006060819A2 (en) 2006-06-08
WO2006060819A3 true WO2006060819A3 (en) 2007-09-20

Family

ID=36565861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/044170 WO2006060819A2 (en) 2004-12-03 2005-12-05 Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells

Country Status (1)

Country Link
WO (1) WO2006060819A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
CN103230394B (en) 2004-12-03 2016-04-20 达纳-法伯癌症研究公司 Compound for the treatment of neoplastic disease and uses thereof
CA2628110A1 (en) * 2005-11-04 2007-05-18 The Regents Of The University Of California Methods of sensitizing cancer to therapy-induced cytotoxicity
WO2008124699A1 (en) * 2007-04-06 2008-10-16 Nereus Pharmaceuticals, Inc. A method of using proteasome inhibitors in combination with histone deacetylase inhibitors to treat cancer
CN103588731B (en) * 2013-12-02 2015-09-02 深圳万和制药有限公司 Salicylamide derivatives and preparation method
CN103588732B (en) * 2013-12-02 2015-03-25 深圳万和制药有限公司 Salicylamide derivative crystal
RU2704020C1 (en) * 2018-06-22 2019-10-23 Общество с ограниченной ответственностью "ПеритонТрит" Combination of dehydroxymethyl epoxyquinomycin (dhmeq) and cytostatics for treating ovarian cancer
RU2703735C1 (en) * 2018-11-09 2019-10-22 Общество с ограниченной ответственностью "ПеритонТрит" Pharmaceutical composition containing dhmeq or its analogues

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271661A1 (en) * 2004-05-17 2005-12-08 Combinatorx, Incorporated Methods and reagents for the treatment of immunoinflammatory disorders
US20060024691A1 (en) * 2004-03-25 2006-02-02 Buck Institute For Age Research Novel pathways in the etiology of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024691A1 (en) * 2004-03-25 2006-02-02 Buck Institute For Age Research Novel pathways in the etiology of cancer
US20050271661A1 (en) * 2004-05-17 2005-12-08 Combinatorx, Incorporated Methods and reagents for the treatment of immunoinflammatory disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIKUCHI E. ET AL.: "Suppression of Hormone-refractory Prostate Cancer by a Novel Nuclear Factor kB Inhibitor in Nude Mice", CANCER RESEARCH, vol. 63, no. 1, January 2003 (2003-01-01), pages 107 - 110, XP002982584 *
MIYAKAWA ET AL.: "Targeting NF-kappaB and Induction of Apoptosis by Dehydroxymethylepoxyquinomicin (DHMEQ) in Multiple Myeloma Cells", BLOOD, vol. 104, November 2004 (2004-11-01) *

Also Published As

Publication number Publication date
WO2006060819A2 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
WO2006060819A3 (en) Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
TW200621240A (en) Cancer treatments
WO2005070043A3 (en) Methods for treating non-melanoma cancers with paba
WO2007033023A3 (en) Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2008077077A3 (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
WO2011031474A3 (en) Use of metformin in cancer treatment and prevention
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
EP2298304A3 (en) Carboline derivatives useful in the treatment of cancer
NZ711695A (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
TN2010000204A1 (en) Kinesin inhibitors as cancer therapeutics
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
WO2007035489A3 (en) Methods of treating or preventing cancer using pyridine carboxaldehyde pyridine thiosemicarbazone radiosensitizing agents
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2005076888A3 (en) Anti-cancer therapies
MX2008015775A (en) Compounds and compositions for treatment of cancer.
ATE509630T1 (en) PANCREAS CANCER TREATMENT WITH NA+/K+-ATPASE INHIBITORS
WO2011056566A3 (en) Compounds and methods for treatment of cancer
WO2005000204A3 (en) Pancreatic cancer treatment
WO2010065563A3 (en) Apratoxin therapeutic agents: mechanism and methods of treatment
WO2008066783A3 (en) Therapeutic materials and methods
HK1079116A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
WO2008084040A8 (en) Use of mage a3-protein d fusion antigen in immunotherapy combined with surgery, chemotherapy or radiotherapy for the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05853161

Country of ref document: EP

Kind code of ref document: A2